Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Many muscle-safety concepts are directionally consistent with the label’s skeletal muscle warning (rare rhabdomyolysis, myopathy risk with higher doses and interacting drugs, and clinical monitoring for muscle effects). However, several specific assertions (e.g., statements about “most people,” “progressive muscle wasting,” typical timing, CK practices “often,” and specific risk factors such as hypothyroidism and large alcohol amounts) are not supported by the provided label excerpts or are too specific beyond what is shown.
Category Scores
Accurate Statements
Statins like atorvastatin can rarely cause rhabdomyolysis with acute renal failure secondary to myoglobinuria.
Label Section 5.1 Skeletal Muscle: “Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported…”
The concomitant use of higher doses of atorvastatin with certain interacting drugs (e.g., cyclosporine and strong CYP3A4 inhibitors) increases risk of myopathy/rhabdomyolysis.
Label Section 5.1 Skeletal Muscle: “The concomitant use of higher doses… with certain drugs such as cyclosporine and strong CYP3A4 inhibitors… increases the risk of myopathy/rhabdomyolysis.” and Label Section 7 overall interaction risk statement.
Risk of myopathy with statins increases with concurrent administration of fibric acid derivatives, niacin (lipid-modifying doses), cyclosporine, or strong CYP3A4 inhibitors.
Label Section 7 (overall interaction risk statement): “The risk of myopathy during treatment with statins is increased with concurrent administration of… fibric acid derivatives… niacin… cyclosporine, or strong CYP 3A4 inhibitors…”
Concomitant strong CYP3A4 inhibitors can lead to increased plasma concentrations of atorvastatin.
Label Section 7.1 Strong Inhibitors of CYP 3A4: “Concomitant administration of LIPITOR with strong inhibitors of CYP 3A4 can lead to increases in plasma concentrations of atorvastatin…”
Clarithromycin, itraconazole, and certain protease inhibitors require caution when atorvastatin dose exceeds 20 mg.
Label Section 7.1: “Clarithromycin… caution… when the LIPITOR dose exceeds 20 mg…”, “Itraconazole… caution… when the LIPITOR dose exceeds 20 mg…”, “Combination of Protease Inhibitors… caution… when the LIPITOR dose exceeds 20 mg…”
There are label-supported dose limits/caution recommendations with cyclosporine (do not exceed 10 mg daily).
Label Section 7.3 Cyclosporine: “…the dose of LIPITOR should not exceed 10 mg.” and Label Section 2.6: “therapy should be limited to… 10 mg once daily.”
Liver function tests are recommended prior to and at 12 weeks after initiation and after any elevation of dose, and periodically thereafter.
Label Section 5.2 Liver Dysfunction: “It is recommended that liver function tests be performed prior to and at 12 weeks following both the initiation of therapy and any elevation of dose…”
Atorvastatin may occasionally cause myopathy, and patients merit closer monitoring for skeletal muscle effects when appropriate.
Label Section 5.1 Skeletal Muscle: “Atorvastatin… occasionally causes myopathy…” and “Such patients merit closer monitoring for skeletal muscle effects.”
Unsupported Statements
For most people, Lipitor (atorvastatin) does not cause muscle loss.
The provided label excerpts do not state “for most people” or quantify incidence of muscle loss/“muscle loss” in that way.
True progressive “muscle loss” in the sense of progressive wasting is uncommon with statins.
The provided excerpts do not support a statement about “progressive wasting” being uncommon/rare.
The main muscle-related concern with atorvastatin is statin-associated muscle symptoms (SAMS).
The label excerpts discuss skeletal muscle outcomes (myopathy, rhabdomyolysis) but do not define or prioritize “SAMS” as the main concern.
SAMS with atorvastatin typically range from mild muscle aches to, very rarely, severe muscle breakdown.
The provided excerpts do not describe the typical spectrum as “mild aches” through “severe muscle breakdown,” nor do they define “SAMS” ranges.
Muscle side effects reported most often with Lipitor are muscle pain, soreness, stiffness, or weakness.
The provided label excerpts list common adverse reactions for discontinuation and common adverse reactions generally, but do not state these as “most often” muscle side effects.
The reported muscle effects from atorvastatin are usually not permanent muscle “loss.”
No provided label excerpt supports the permanence/“usually not permanent” characterization.
Atorvastatin-associated muscle symptoms often improve when the dose changes or the statin is stopped.
The provided excerpts do not state that muscle symptoms often improve with dose change or discontinuation.
Severe muscle injury associated with statins is much rarer than mild SAMS.
The provided excerpts state rhabdomyolysis is rare, but do not compare severity “much rarer than mild SAMS” or support relative frequency vs “SAMS.”
Severe statin-associated muscle injury is associated with marked muscle damage.
The provided excerpts mention rhabdomyolysis/myoglobinuria risk but do not support the specific characterization “marked muscle damage.”
Severe statin-associated muscle injury can come with very high creatine kinase (CK).
CK thresholds/“very high CK” are not present in the provided excerpts.
Severe statin-associated muscle injury can come with darker urine.
The provided excerpts mention myoglobinuria (which can relate to dark urine), but the specific phrase/claim “darker urine” is not explicitly supported in the provided text.
Risk for serious muscle injury from atorvastatin is higher with higher statin doses.
The label excerpts support increased risk with higher doses in the context of certain interacting drugs (e.g., cyclosporine/CYP3A4 inhibitors), but do not broadly support this statement for atorvastatin dose alone across all situations in the provided excerpts.
Risk for serious muscle injury from atorvastatin is higher in older age.
No older-age risk factor for skeletal muscle outcomes is provided in the excerpts.
Risk for serious muscle injury from atorvastatin is higher with kidney or liver disease.
The provided excerpts do not state kidney or liver disease increases skeletal muscle injury risk (they state renal disease does not affect plasma concentrations/LDL-C reduction, and liver function monitoring/contraindication, but not as a risk factor for muscle injury).
Risk for serious muscle injury from atorvastatin is higher with certain drug interactions that increase statin exposure (for example, some antibiotics/antifungals or other medications that raise statin levels).
The examples are not explicitly supported as stated; while the label supports strong CYP3A4 inhibitors and provides specific agents, the generalized “antibiotics/antifungals” framing is not supported in the provided excerpts.
Risk for serious muscle injury from atorvastatin is higher with hypothyroidism.
Not supported by the provided excerpts.
Risk for serious muscle injury from atorvastatin is higher with large amounts of alcohol use.
Not supported by the provided excerpts.
Statin muscle symptoms usually develop after starting the drug or after dose increases.
The provided excerpts do not describe typical timing of muscle symptom onset.
Statin muscle symptoms often develop within the first weeks to months.
Not supported by the provided excerpts.
Statin muscle symptoms can occur at other times too.
No timing flexibility is discussed in the provided excerpts.
Persistent or worsening weakness should be assessed promptly rather than assumed to be harmless.
No guidance in the provided excerpts uses this wording or specifies prompt assessment for weakness.
Clinicians often check creatine kinase (CK) levels when evaluating new unexplained muscle symptoms in patients taking statins.
CK monitoring is not mentioned in the provided label excerpts.
Clinicians often review medication interactions when evaluating statin-associated muscle symptoms.
The label addresses interacting agents and caution/dose limits, but the provided excerpts do not state clinician practice patterns about “often” reviewing interactions.
Management of statin-associated muscle symptoms can include dose reduction.
The provided excerpts include dosage limits with interacting drugs but do not state a management recommendation of dose reduction for muscle symptoms.
Management of statin-associated muscle symptoms can include switching statins.
Not supported by the provided excerpts.
Management of statin-associated muscle symptoms can include addressing contributing conditions like hypothyroidism.
Hypothyroidism is not discussed in the provided excerpts.
Long-term true muscle wasting is not typical of statin side effects.
Not supported by provided excerpts.
Statins are not a common cause of progressive muscle loss.
Not supported by the provided excerpts.
Lowering the atorvastatin dose is an option if muscle symptoms occur.
Dose reduction for muscle symptoms is not explicitly described in the provided excerpts (dose adjustments exist for interacting drugs/populations, but not as a direct symptom-management option).
Changing to a different statin is an option if muscle symptoms occur.
Not supported by the provided excerpts.
Non-statin lipid-lowering therapy depending on LDL-C needs and overall cardiovascular risk is an alternative option if muscle symptoms happen.
The provided excerpts do not discuss switching to non-statin lipid therapies specifically for muscle symptoms.
Contradictions
Low
AI Statement
Risk for serious muscle injury from atorvastatin is higher with kidney or liver disease.
Label Reference
No contradiction is shown in the provided excerpts; however, it is not supported. (No direct contradiction in provided text.)
Important Omissions
Specific on-label skeletal muscle monitoring/management language is missing relative to the label details (e.g., “Such patients merit closer monitoring for skeletal muscle effects” and the dose-limit/caution guidance with interacting agents summarized in Table 1).
Importance:
Moderate
Liver dysfunction monitoring and contraindications are not addressed in the claims, though they are part of the label safety section; while not asked explicitly, these are material for medication safety beyond muscle effects.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several statements about incidence/spectrum, CK testing, symptom timing, and management options are not supported by the provided label excerpts. While the label supports skeletal muscle risk (including rare rhabdomyolysis) and increased risk with certain interacting drugs/higher doses in that context, the unsupported specificity could mislead about what is “typical,” how often clinicians check CK, and what management steps are label-supported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Over-specific claims about SAMS spectrum, timing, monitoring (CK), and multiple risk factors (hypothyroidism, alcohol use, older age, kidney/liver disease) are not supported by the provided label excerpts.
Suggested Improvement
Limit statements to what the provided label excerpts support: rare rhabdomyolysis with myoglobinuria, occasional myopathy, increased risk with interacting drugs (fibric acid derivatives, niacin, cyclosporine, strong CYP3A4 inhibitors) and dose-limit/caution recommendations (e.g., do not exceed 10 mg with cyclosporine; caution when exceeding 20 mg with clarithromycin/itraconazole/protease inhibitors). Avoid unlabelled frequency/timing and CK/darker-urine/management specifics unless included in the label text provided.